Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme

BACKGROUND: Androgen suppression is a central component of prostate cancer management but causes substantial long-term toxicity. Transdermal administration of oestradiol (tE2) circumvents first-pass hepatic metabolism and, therefore, should avoid the cardiovascular toxicity seen with oral oestrogen...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Lancet
Main Authors: Langley, Ruth E, Gilbert, Duncan C, Duong, Trinh, Clarke, Noel W, Nankivell, Matthew, Rosen, Stuart D, Mangar, Stephen, Macnair, Archie, Sundaram, Subramanian Kanaga, Laniado, Marc E, Dixit, Sanjay, Madaan, Sanjeev, Manetta, Caroline, Pope, Alvan, Scrase, Christopher D, Mckay, Stephen, Muazzam, Iqtedar A, Collins, Gerald N, Worlding, Jane, Williams, Simon T, Paez, Edgar, Robinson, Angus, McFarlane, Jonathan, Deighan, John V, Marshall, John, Forcat, Silvia, Weiss, Melanie, Kockelbergh, Roger, Alhasso, Abdulla, Kynaston, Howard, Parmar, Mahesh
Format: Artigo
Sprog:Inglês
Udgivet: 2021
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7614681/
https://ncbi.nlm.nih.gov/pubmed/33581820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(21)00100-8
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker